Review article: A comparison of glucagon-like peptides 1 and 2

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 1, 2013, Pages 18-36

  Janssen, P ^a   Rotondo, A ^b   Mule F ^b   Tack, J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; FE 203799; GASTROINTESTINAL AGENT; GATTEX; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 2 RECEPTOR; HORMONE RECEPTOR; LIRAGLUTIDE; PLACEBO; SULFONYLUREA; TEDUGLUTIDE; UNCLASSIFIED DRUG; VILDAGLIPTIN; ZP 1846; ZP 1848;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADVERSE OUTCOME; CELL PROLIFERATION; COLON CANCER; CROHN DISEASE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENTEROPATHY; GASTROINTESTINAL SYMPTOM; HUMAN; MOLECULAR DYNAMICS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ONTOGENY; PANCREAS ISLET BETA CELL; PANCREATITIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REVIEW; SHORT BOWEL SYNDROME; STOMACH EMPTYING; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, GLUCAGON;

EID: 84870620612     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12092     Document Type: Review

References (205)

1. Baggio LL, Drucker DJ,. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. Best Pract Res Clin Endocrinol Metab 2004; 18: 531-54.
2. Holst JJ,. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-39.
3. Drucker DJ,. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-40.
4. Estall JL, Drucker DJ,. Glucagon-like peptide-2. Annu Rev Nutr 2006; 26: 391-411.
5. Hornby PJ, Moore BA,. The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease. Expert Opin Ther Targets 2011; 15: 637-46.
6. Wallis K, Walters JR, Forbes A,. Review article: glucagon-like peptide 2-current applications and future directions. Aliment Pharmacol Ther 2007; 25: 365-72.
7. Drucker DJ, Asa S,. Glucagon gene expression in vertebrate brain. J Biol Chem 1988; 263: 13475-8.
8. Drucker DJ, Brubaker PL,. Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine. Proc Natl Acad Sci U S A 1989; 86: 3953-7.
9. Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, Orskov C,. Proglucagon processing in porcine and human pancreas. J Biol Chem 1994; 269: 18827-33.
10. Rouille Y, Kantengwa S, Irminger JC, Halban PA,. Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1. J Biol Chem 1997; 272: 32810-6.
11. Ugleholdt R, Zhu X, Deacon CF, Orskov C, Steiner DF, Holst JJ,. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1. Endocrinology 2004; 145: 1349-55.
12. Wideman RD, Yu IL, Webber TD, et al,. Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc Natl Acad Sci U S A 2006; 103: 13468-73.
13. Zhu X, Zhou A, Dey A, et al,. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc Natl Acad Sci U S A 2002; 99: 10293-8.
14. Lim GE, Brubaker PL,. Glucagon-like peptide 1 secretion by the L cell. Diabetes 2006; 55 (Suppl. 2): S70-7.
15. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV,. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986; 119: 1467-75.
16. Brubaker PL,. The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis. Ann N Y Acad Sci 2006; 1070: 10-26.
17. Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B,. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56: 117-26.
18. Reimann F, Ward PS, Gribble FM,. Signaling mechanisms underlying the release of glucagon-like peptide-1. Diabetes 2006; 55 (Suppl. 2): S78-85.
19. Xiao Q, Boushey RP, Drucker DJ, Brubaker PL,. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 1999; 117: 99-105.
20. Nauck MA, Kemmeries G, Holst JJ, Meier JJ,. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011; 60: 1561-5.
21. Cummings DE, Overduin J,. Gastrointestinal regulation of food intake. J Clin Invest 2007; 117: 13-23.
22. Reimann F, Gribble FM,. Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 2002; 51: 2757-63.
23. Rocca AS, Brubaker PL,. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999; 140: 1687-94.
24. Anini Y, Brubaker PL,. Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology 2003; 144: 3244-50.
25. Roberge JN, Gronau KA, Brubaker PL,. Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. Endocrinology 1996; 137: 2383-8.
26. Brubaker PL,. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology 1991; 128: 3175-82.
27. Deacon CF, Johnsen AH, Holst JJ,. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-7.
28. Kieffer TJ, McIntosh CH, Pederson RA,. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-96.
29. Tavares W, Drucker DJ, Brubaker PL,. Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab 2000; 278: E134-9.
30. Brubaker PL, Crivici A, Izzo A, Ehrlich P, Tsai CH, Drucker DJ,. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology 1997; 138: 4837-43.
31. Hansen L, Deacon CF, Orskov C, Holst JJ,. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140: 5356-63.
32. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jorgensen PN, Holst JJ,. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 2000; 278: E1010-8.
33. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ,. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-31.
34. Drucker DJ, Shi Q, Crivici A, et al,. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 1997; 15: 673-7.
35. Hartmann B, Harr MB, Jeppesen PB, et al,. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 2000; 85: 2884-8.
36. Ruiz-Grande C, Pintado J, Alarcon C, Castilla C, Valverde I, Lopez-Novoa JM,. Renal catabolism of human glucagon-like peptides 1 and 2. Can J Physiol Pharmacol 1990; 68: 1568-73.
37. Meier JJ, Nauck MA, Kranz D, et al,. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004; 53: 654-62.
38. Wallis K, Walters JR, Gabe S,. Short bowel syndrome: the role of GLP-2 on improving outcome. Curr Opin Clin Nutr Metab Care 2009; 12: 526-32.
39. Munroe DG, Gupta AK, Kooshesh F, et al,. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A 1999; 96: 1569-73.
40. Baggio LL, Drucker DJ,. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-57.
41. Wheeler MB, Lu M, Dillon JS, Leng XH, Chen C, Boyd AE 3rd,. Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology 1993; 133: 57-62.
42. Bullock BP, Heller RS, Habener JF,. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137: 2968-78.
43. Campos RV, Lee YC, Drucker DJ,. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994; 134: 2156-64.
44. Dunphy JL, Taylor RG, Fuller PJ,. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 1998; 141: 179-86.
45. Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS,. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 2008; 56: 841-51.
46. Nakagawa A, Satake H, Nakabayashi H, et al,. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004; 110: 36-43.
47. Amato A, Cinci L, Rotondo A, et al,. Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors. Neurogastroenterol Motil 2010; 22: 664-e203.
48. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP,. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995; 7: 2294-300.
49. Bucinskaite V, Tolessa T, Pedersen J, et al,. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil 2009; 21: 978-e78.
50. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB,. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997; 273: G920-7.
51. Yusta B, Huang L, Munroe D, et al,. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000; 119: 744-55.
52. Nelson DW, Sharp JW, Brownfield MS, Raybould HE, Ney DM,. Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. Endocrinology 2007; 148: 1954-62.
53. Angelone T, Filice E, Quintieri AM, et al,. Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart. Nutr Metab Cardiovasc Dis 2012; 22: 486-94.
54. Lovshin J, Estall J, Yusta B, Brown TJ, Drucker DJ,. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol Chem 2001; 276: 21489-99.
55. Lovshin JA, Huang Q, Seaberg R, Brubaker PL, Drucker DJ,. Extrahypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells. Endocrinology 2004; 145: 3495-506.
56. Bjerknes M, Cheng H,. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci U S A 2001; 98: 12497-502.
57. Orskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ,. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 2005; 124: 105-12.
58. Amato A, Rotondo A, Cinci L, Baldassano S, Vannucchi MG, Mule F,. Role of cholinergic neurons in the motor effects of glucagon-like peptide-2 in mouse colon. Am J Physiol Gastrointest Liver Physiol 2010; 299: G1038-44.
59. Sinclair EM, Drucker DJ,. Proglucagon-derived peptides: mechanisms of action and therapeutic potential. Physiology (Bethesda) 2005; 20: 357-65.
60. Guan X, Karpen HE, Stephens J, et al,. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006; 130: 150-64.
61. Guan X, Stoll B, Lu X, et al,. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology 2003; 125: 136-47.
62. Dube PE, Rowland KJ, Brubaker PL,. Glucagon-like peptide-2 activates beta-catenin signaling in the mouse intestinal crypt: role of insulin-like growth factor-I. Endocrinology 2008; 149: 291-301.
63. Liu X, Murali SG, Holst JJ, Ney DM,. Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1794-802.
64. Nelson DW, Murali SG, Liu X, Koopmann MC, Holst JJ, Ney DM,. Insulin-like growth factor I and glucagon-like peptide-2 responses to fasting followed by controlled or ad libitum refeeding in rats. Am J Physiol Regul Integr Comp Physiol 2008; 294: R1175-84.
65. Bahrami J, Yusta B, Drucker DJ,. ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel. Gastroenterology 2010; 138: 2447-56.
66. Yusta B, Holland D, Koehler JA, et al,. ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology 2009; 137: 986-96.
67. Sigalet DL, Wallace LE, Holst JJ, et al,. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2007; 293: G211-21.
68. Amato A, Baldassano S, Serio R, Mule F,. Glucagon-like peptide-2 relaxes mouse stomach through vasoactive intestinal peptide release. Am J Physiol Gastrointest Liver Physiol 2009; 296: G678-84.
69. Cinci L, Faussone-Pellegrini MS, Rotondo A, Mule F, Vannucchi MG,. GLP-2 receptor expression in excitatory and inhibitory enteric neurons and its role in mouse duodenum contractility. Neurogastroenterol Motil 2011; 23: e383-92.
70. Dube PE, Brubaker PL,. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 2007; 293: E460-5.
71. Rowland KJ, Brubaker PL,. The "cryptic" mechanism of action of glucagon-like peptide-2. Am J Physiol Gastrointest Liver Physiol 2011; 301: G1-8.
72. Lovshin J, Yusta B, Iliopoulos I, et al,. Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine. Endocrinology 2000; 141: 4194-201.
73. Sigalet DL, Martin G, Meddings J, Hartman B, Holst JJ,. GLP-2 levels in infants with intestinal dysfunction. Pediatr Res 2004; 56: 371-6.
74. Amin H, Holst JJ, Hartmann B, Wallace L, Wright J, Sigalet DL,. Functional ontogeny of the proglucagon-derived peptide axis in the premature human neonate. Pediatrics 2008; 121: e180-6.
75. Drucker DJ,. Glucagon-like peptide 2. J Clin Endocrinol Metab 2001; 86: 1759-64.
76. Orskov C, Bersani M, Johnsen AH, Hojrup P, Holst JJ,. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J Biol Chem 1989; 264: 12826-9.
77. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ,. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994; 43: 535-9.
78. Orskov C, Wettergren A, Holst JJ,. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993; 42: 658-61.
79. Fehmann HC, Habener JF,. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992; 130: 159-66.
80. Orskov C, Holst JJ, Nielsen OV,. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988; 123: 2009-13.
81. Tang-Christensen M, Larsen PJ, Goke R, et al,. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271: R848-56.
82. Flint A, Raben A, Astrup A, Holst JJ,. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-20.
83. Gutzwiller JP, Goke B, Drewe J, et al,. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999; 44: 81-6.
84. Gutzwiller JP, Tschopp S, Bock A, et al,. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89: 3055-61.
85. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM,. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 1998; 68: 525-30.
86. Verdich C, Flint A, Gutzwiller JP, et al,. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86: 4382-9.
87. Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ,. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 1997; 40: 597-601.
88. Daniel EE, Anvari M, Fox-Threlkeld JE, McDonald TJ,. Local, exendin-(9-39)-insensitive, site of action of GLP-1 in canine ileum. Am J Physiol Gastrointest Liver Physiol 2002; 283: G595-602.
89. Giralt M, Vergara P,. Glucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat. Dig Dis Sci 1999; 44: 322-9.
90. Miki T, Minami K, Shinozaki H, et al,. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes 2005; 54: 1056-63.
91. Schirra J, Wank U, Arnold R, Goke B, Katschinski M,. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut 2002; 50: 341-8.
92. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM,. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Invest 1998; 102: 764-74.
93. Anvari M, Paterson CA, Daniel EE, McDonald TJ,. Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid. Dig Dis Sci 1998; 43: 1133-40.
94. Rotondo A, Amato A, Lentini L, Baldassano S, Mule F,. Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice. Peptides 2011; 32: 60-4.
95. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM,. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998; 43: 2284-90.
96. Wettergren A, Wojdemann M, Holst JJ,. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998; 275: G984-92.
97. Wishart JM, Horowitz M, Morris HA, Jones KL, Nauck MA,. Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. Peptides 1998; 19: 1049-53.
98. Linnebjerg H, Park S, Kothare PA, et al,. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008; 151: 123-9.
99. Andrews CN, Bharucha AE, Camilleri M, et al,. Nitrergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1359-65.
100. Andrews CN, Bharucha AE, Camilleri M, et al,. Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans. Neurogastroenterol Motil 2007; 19: 716-23.
101. Delgado-Aros S, Kim DY, Burton DD, et al,. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 2002; 282: G424-31.
102. Naslund E, Bogefors J, Gryback P, et al,. GLP-1 inhibits gastric emptying of water but does not influence plasma. Scand J Gastroenterol 2001; 36: 156-62.
103. Farilla L, Bulotta A, Hirshberg B, et al,. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149-58.
104. Hui H, Wright C, Perfetti R,. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 2001; 50: 785-96.
105. Kim JG, Baggio LL, Bridon DP, et al,. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003; 52: 751-9.
106. Sturis J, Gotfredsen CF, Romer J, et al,. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003; 140: 123-32.
107. Xu G, Stoffers DA, Habener JF, Bonner-Weir S,. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-6.
108. Knauf C, Cani PD, Perrin C, et al,. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005; 115: 3554-63.
109. Li Y, Xu W, Tang L, Gong M, Zhang J,. A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo. Peptides 2011; 32: 1408-14.
110. Pinelli NR, Hurren KM,. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Pharmacother 2011; 45: 850-60.
111. Portha B, Tourrel-Cuzin C, Movassat J,. Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res 2011; 2011: 376509.
112. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ,. An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011; 13: 394-407.
113. Tanaka T, Nangaku M, Nishiyama A,. The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors. Curr Opin Nephrol Hypertens 2011; 20: 476-81.
114. Drucker DJ, Nauck MA,. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
115. Kendall DM, Riddle MC, Rosenstock J, et al,. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-91.
116. Zinman B, Gerich J, Buse JB, et al,. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-30.
117. Nielsen LL, Young AA, Parkes DG,. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 77-88.
118. Peters KR,. Liraglutide for the treatment of type 2 diabetes: a clinical update. Am J Ther 2011; doi: 10.1097/MJT.0b013e3182204c16 [Epub ahead of print].
119. Thong KY, Jose B, Sukumar N, et al,. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab 2011; 13: 703-10.
120. Xiao C, Bandsma RH, Dash S, Szeto L, Lewis GF,. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler Thromb Vasc Biol 2012; 32: 1513-9.
121. Byetta (exenatide). Full Prescribing Information. Amylin Pharmaceuticals, San Diego, CA, 2011.
122. Victoza (liraglutide). Full Prescribing Information. Novo Nordisk A/S, Bagsvaerd, Denmark, 2011.
123. Kunkel D, Basseri B, Low K, et al,. Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome. Neurogastroenterol Motil 2011; 23: 739-e328.
124. Buse JB, Henry RR, Han J, et al,. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-35.
125. Garber A, Henry R, Ratner R, et al,. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-81.
126. Knudsen LB, Nielsen PF, Huusfeldt PO, et al,. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 1664-9.
127. Marre M, Shaw J, Brandle M, et al,. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-78.
128. Moretto TJ, Milton DR, Ridge TD, et al,. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008; 30: 1448-60.
129. Parks M, Rosebraugh C,. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010; 362: 774-7.
130. Blomgren KB, Sundstrom A, Steineck G, Wiholm BE,. Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diabetes Care 2002; 25: 298-302.
131. Yamamoto H, Lee CE, Marcus JN, et al,. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110: 43-52.
132. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM,. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54: 146-51.
133. Nikolaidis LA, Elahi D, Hentosz T, et al,. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110: 955-61.
134. Nystrom T, Gutniak MK, Zhang Q, et al,. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209-15.
135. Drucker DJ, Erlich P, Asa SL, Brubaker PL,. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 1996; 93: 7911-6.
136. Baldassano S, Liu S, Qu MH, Mule F, Wood JD,. Glucagon-like peptide-2 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro. Am J Physiol Gastrointest Liver Physiol 2009; 297: G800-5.
137. Thulesen J, Knudsen LB, Hartmann B, et al,. The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept 2002; 103: 9-15.
138. Kim W, Egan JM,. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470-512.
139. Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ,. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol Endocrinol Metab 1997; 273: E77-84.
140. Tsai CH, Hill M, Drucker DJ,. Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am J Physiol 1997; 272: G662-8.
141. Drucker DJ, DeForest L, Brubaker PL,. Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2. Am J Physiol 1997; 273: G1252-62.
142. Leen JL, Izzo A, Upadhyay C, et al,. Mechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts. Endocrinology 2011; 152: 436-46.
143. Dube PE, Forse CL, Bahrami J, Brubaker PL,. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology 2006; 131: 589-605.
144. Koopmann MC, Nelson DW, Murali SG, et al,. Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats. JPEN 2008; 32: 254-65.
145. Koopmann MC, Chen X, Holst JJ, Ney DM,. Sustained glucagon-like peptide-2 infusion is required for intestinal adaptation, and cessation reverses increased cellularity in rats with intestinal failure. Am J Physiol Gastrointest Liver Physiol 2010; 299: G1222-30.
146. Martin GR, Wallace LE, Hartmann B, et al,. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2005; 288: G431-8.
147. Shin ED, Estall JL, Izzo A, Drucker DJ, Brubaker PL,. Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology 2005; 128: 1340-53.
148. Jeppesen PB, Hartmann B, Thulesen J, et al,. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2000; 47: 370-6.
149. Caddy GR, Ardill JE, Fillmore D, et al,. Plasma concentrations of glucagon-like peptide-2 in adult patients with treated and untreated coeliac disease. Eur J Gastroenterol Hepatol 2006; 18: 195-202.
150. Chance WT, Foley-Nelson T, Thomas I, Balasubramaniam A,. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am J Physiol 1997; 273: G559-63.
151. Schmidt PT, Hartmann B, Bregenholt S, Hoist JJ, Claesson MH,. Deficiency of the intestinal growth factor, glucagon-like peptide 2, in the colon of SCID mice with inflammatory bowel disease induced by transplantation of CD4 + T cells. Scand J Gastroenterol 2000; 35: 522-7.
152. Martin GR, Wallace LE, Sigalet DL,. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2004; 286: G964-72.
153. Jeppesen PB, Hartmann B, Thulesen J, et al,. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001; 120: 806-15.
154. Jeppesen PB, Sanguinetti EL, Buchman A, et al,. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005; 54: 1224-31.
155. Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst JJ, Mortensen PB,. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 1999; 45: 559-63.
156. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH,. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 2000; 47: 112-9.
157. Cameron HL, Perdue MH,. Stress impairs murine intestinal barrier function: improvement by glucagon-like peptide-2. J Pharmacol Exp Ther 2005; 314: 214-20.
158. Cameron HL, Yang PC, Perdue MH,. Glucagon-like peptide-2-enhanced barrier function reduces pathophysiology in a model of food allergy. Am J Physiol Gastrointest Liver Physiol 2003; 284: G905-12.
159. Hadjiyanni I, Li KK, Drucker DJ,. Glucagon-like peptide-2 reduces intestinal permeability but does not modify the onset of type 1 diabetes in the nonobese diabetic mouse. Endocrinology 2009; 150: 592-9.
160. Cani PD, Possemiers S, Van de Wiele T, et al,. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58: 1091-103.
161. Hsieh J, Longuet C, Maida A, et al,. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology 2009; 137: 997-1005, e1-4.
162. Kato Y, Yu D, Schwartz MZ,. Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J Pediatr Surg 1999; 34: 18-20.
163. Meier JJ, Nauck MA, Pott A, et al,. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006; 130: 44-54.
164. Brubaker PL, Izzo A, Hill M, Drucker DJ,. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 1997; 272: E1050-8.
165. Au A, Gupta A, Schembri P, Cheeseman CI,. Rapid insertion of GLUT2 into the rat jejunal brush-border membrane promoted by glucagon-like peptide 2. Biochem J 2002; 367: 247-54.
166. Cheeseman CI,. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am J Physiol 1997; 273: R1965-71.
167. Petersen YM, Elnif J, Schmidt M, Sangild PT,. Glucagon-like peptide 2 enhances maltase-glucoamylase and sucrase-isomaltase gene expression and activity in parenterally fed premature neonatal piglets. Pediatr Res 2002; 52: 498-503.
168. Stephens J, Stoll B, Cottrell J, Chang X, Helmrath M, Burrin DG,. Glucagon-like peptide-2 acutely increases proximal small intestinal blood flow in TPN-fed neonatal piglets. Am J Physiol Regul Integr Comp Physiol 2006; 290: R283-9.
169. Bremholm L, Hornum M, Henriksen BM, Larsen S, Holst JJ,. Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol 2009; 44: 314-9.
170. Wojdemann M, Wettergren A, Hartmann B, Hilsted L, Holst JJ,. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999; 84: 2513-7.
171. Wojdemann M, Wettergren A, Hartmann B, Holst JJ,. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998; 33: 828-32.
172. Schmidt PT, Naslund E, Gryback P, et al,. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 2003; 116: 21-5.
173. Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ,. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand J Gastroenterol 2004; 39: 353-8.
174. Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, Vrang N,. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 2000; 6: 802-7.
175. McDonagh SC, Lee J, Izzo A, Brubaker PL,. Role of glial cell-line derived neurotropic factor family receptor alpha2 in the actions of the glucagon-like peptides on the murine intestine. Am J Physiol Gastrointest Liver Physiol 2007; 293: G461-8.
176. Sorensen LB, Flint A, Raben A, Hartmann B, Holst JJ, Astrup A,. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metab Disord 2003; 27: 450-6.
177. Baldassano S, Bellanca AL, Serio R, Mule F,. Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2. J Endocrinol 2012; 213: 277-84.
178. Vrang N, Larsen PJ,. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides. Prog Neurobiol 2010; 92: 442-62.
179. Velazquez E, Blazquez E, Ruiz-Albusac JM,. Synergistic effect of glucagon-like peptide 2 (GLP-2) and of key growth factors on the proliferation of cultured rat astrocytes. Evidence for reciprocal upregulation of the mRNAs for GLP-2 and IGF-I receptors. Mol Neurobiol 2009; 40: 183-93.
180. Velazquez E, Ruiz-Albusac JM, Blazquez E,. Glucagon-like peptide-2 stimulates the proliferation of cultured rat astrocytes. Eur J Biochem 2003; 270: 3001-9.
181. Voss U, Sand E, Hellstrom PM, Ekblad E,. Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons. BMC Gastroenterol 2012; 12: 30.
182. Iwai T, Hayashi Y, Narita S, et al,. Antidepressant-like effects of glucagon-like peptide-2 in mice occur via monoamine pathways. Behav Brain Res 2009; 204: 235-40.
183. Liu X, Nelson DW, Holst JJ, Ney DM,. Synergistic effect of supplemental enteral nutrients and exogenous glucagon-like peptide 2 on intestinal adaptation in a rat model of short bowel syndrome. Am J Clin Nutr 2006; 84: 1142-50.
184. Scott RB, Kirk D, MacNaughton WK, Meddings JB,. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol 1998; 275 (5 Pt 1): G911-21.
185. Washizawa N, Gu LH, Gu L, Openo KP, Jones DP, Ziegler TR,. Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats. JPEN J Parenter Enteral Nutr 2004; 28: 399-409.
186. Booth C, Booth D, Williamson S, Demchyshyn LL, Potten CS,. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif 2004; 37: 385-400.
187. Boushey RP, Yusta B, Drucker DJ,. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 1999; 277: E937-47.
188. Boushey RP, Yusta B, Drucker DJ,. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 2001; 61: 687-93.
189. Yamazaki K, Yasuda N, Inoue T, et al,. The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight. Eur J Pharmacol 2004; 488: 213-8.
190. Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG,. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 2010; 16: 962-73.
191. Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ,. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011; 60: 902-14.
192. Skarbaliene J, Petersen YM, Christjansen K, Ebbehoej K, Pedersen HD, Thorkildsen C,. ZP1848, a novel GLP-2 agonist, provides a wide window of therapeutic efficacy in the experimental Crohn's disease model. Gastroenterology 2011; 140 (Suppl. 1): S519.
193. Petersen YM, Jepsen T, Thorkildsen C, Larsen BD, Petersen JS, Kjolbye A,. ZP1846, a novel stable, high efficacy glucagon-like peptide 2 mimetic, stimulates small intestinal growth and prevents 5-fluorouracil-induced small intestinal injury in C57BL mice. Gut 2006; 55: A48.
194. Petersen YM, Thorkildsen C, Petersen JS, Kjolbye A,. ZP1846, a novel potential candidate for the treatment of chemotherapy-induced diarrhea. Support Care Cancer 2007; 15: 772-3.
195. Hargrove DM, Alagarsamy S, Qi S, et al,. Pharmacological characterization of FE 203799, a novel long-acting peptide analog of glucagon-like peptide-2 (GLP-2). Gastroenterology 2011; 140 (Suppl. 1): S293.
196. Schwartz LK, Seidner DL, Jeppesen PB, Pertkiewicz M, Youssef N, Heinze H,. Teduglutide (TED) for the treatment of short bowel syndrome-intestinal failure (SBS-IF) subjects yields further reductions in parenteral support (PS): an interim assessment of a 2-year, open-label, phase 3 trial (STEPS2). Am J Gastroenterol 2011; 106: S99.
197. Koehler JA, Yusta B, Drucker DJ,. The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol Endocrinol 2005; 19: 459-73.
198. Bengi G, Kayahan H, Akarsu M, et al,. Does glucagon like peptide-2 receptor expression have any effect on the development of human colorectal cancer? Turk J Gastroenterol 2011; 22: 388-94.
199. Iakoubov R, Lauffer LM, Trivedi S, Kim YI, Brubaker PL,. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology 2009; 150: 4033-43.
200. Thulesen J, Hartmann B, Hare KJ, et al,. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 2004; 53: 1145-50.
201. Koehler JA, Harper W, Barnard M, Yusta B, Drucker DJ,. Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Cancer Res 2008; 68: 7897-904.
202. Trivedi S, Wiber SC, El-Zimaity HM, Brubaker PL,. Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer. Am J Physiol Gastrointest Liver Physiol 2012; 302: G840-9.
203. Rowland KJ, Trivedi S, Lee D, et al,. Loss of glucagon-like peptide-2-induced proliferation following intestinal epithelial insulin-like growth factor-1-receptor deletion. Gastroenterology 2011; 141: 2166-75, e7.
204. Tee CT, Wallis K, Gabe SM,. Emerging treatment options for short bowel syndrome: potential role of teduglutide. Clin Exp Gastroenterol 2011; 4: 189-96.
205. Johansen OE, Whitfield R,. Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol 2008; 66: 568-9.